The relationship between pre-surgical intra-articular injection and risk for early revision and infection following total hip arthroplasty  by Ravi, B. et al.
Abstracts / Osteoarthritis and Cartilage 21 (2013) S9–S62S10United Kingdom; xCtr. of Clinical and Basic Res., Ballerup, Denmark;
kDept. of Rheumatology, Leiden Univ., Leiden, Netherlands
Purpose: There are several types of inﬂammatory arthritis’, with
rheumatoid arthritis (RA) as the most common. Inﬂammatory arthritic
diseases have different pathologies, but they share features, such as
joint inﬂammation and tissue destruction. It is important to treat fast
progressors aggressively in these diseases to preserve joint function.
However, presently it is not possible to identify progressors based on
standard technologies. Identiﬁcation of the patients in most need of
treatment is also important as most anti-inﬂammatory treatments are
associated with substantial side effects. Thus, limiting the patient
population in need to be treated with a certain biological agent will
improve the risk-beneﬁt ratio. We have developed and validated an
ELISA, detecting a serum protein ﬁngerprint of the helical domain of
type I collagen, speciﬁcally degraded by MMP's and destroyed by
Cathepsin K (C1M). The ELISA does not recognise other collagens, intact
collagen or other protein ﬁngerprints. The aim of the present study was
to investigate whether serological levels of C1M could identify struc-
tural progression and if C1M could be a marker of treatment efﬁcacy.
Methods: The LITHE biomarker study (n¼585) is a 1-year phase III,
double-blind, placebo (PBO)-controlled, parallel group study of Tocili-
zumab (TCZ) 4 or 8 mg/kg in RA patients on stable doses of metho-
trexate (MTX). Spearman's rank correlation was used to assess the
correlation between baseline C1M and inﬂammation (CRP), visual
analogue score pain (VAS), general health (HAQ), disease activity score
(DAS)-28-ESR and structural progression (joint space narrowing (JSN)
and modiﬁed total Sharp Score (mTSS)) at 24 and 52 weeks. Multiple
regression analysis on log-transformed data was used to assess the
effect of cofounders (CRP, age, BMI, disease duration and baseline
structural status) on baseline C1M with JSN and mTSS.
Results: At baseline, C1M was signiﬁcantly correlated to CRP
(P<0.0001), VAS pain (P<0.0001), HAQ (P<0.0001), DAS28-ESR
(P<0.0001), JSN (P¼0.0056) and mTSS (P¼0.0006). There was a corre-
lation between baseline C1M and delta-mTSS at 24 weeks (R2¼0.28,
P¼0.0084) and strongly at 52 week (R2¼0.34, p<0.0017, see table).
Baseline C1M was signiﬁcantly correlated to change in CRP at 24
(R2¼-0.31, P¼0.001) and 52 weeks (R2¼-0.36, P¼0.007). There was
a tendency for baseline C1M to be correlated with delta-JSN at week 52
(R2¼0.21, p<0.055), but not at week 24. This was conﬁrmed bymultiple
regression, in which CRP was the only confounder on effect size; beta
changed from 1.4 to 3.6 with JSN and from 3.4 to 6.0 with mTSS (Table).
The adjusted correlation coefﬁcients were 0.31 and 0.32 for delta JSN
and mTSS, respectively.
Conclusions: Serum C1M measured at baseline was correlated to
change in structural progression. In conclusion, C1M may enable
prognostic identiﬁcation of those patients who are structural pro-
gressors in inﬂammatory arthritis.Multivariate linear regression analysis. Beta, regression coefﬁcient, p-value and
n are given.
D52 weeks (JSN) D52 weeks (mTSS)
Beta P R2model n Beta P R
2
model n
LogC1M 1.4 0.0015 0.11 85 3.4 0.0001 0.17 85










3.6 <0.0001 0.31 83 6.0 <0.0001 0.32 833
THE RELATIONSHIP BETWEEN PRE-SURGICAL INTRA-ARTICULAR
INJECTION AND RISK FOR EARLY REVISION AND INFECTION
FOLLOWING TOTAL HIP ARTHROPLASTY
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ON, CanadaPurpose: Intra-articular hip injections of corticosteroids or hyaluronic
acid are recommended in the management of hip osteoarthritis (OA).
While some studies have found that a subsequent total hip arthroplasty
(THA) is at risk for early revision, purportedly because of infection, these
ﬁndings are not consistent. Potential explanations for the inconsistency
of ﬁndings include variability in sample sizes, and thus power, duration
between the injection and arthroplasty, and control for potential
confounders. We sought to determine the proportion of patients who
had an intra-articular injection prior to their THA and the relationship
between pre-THA injection and risk for early revision.
Methods: We deﬁned a cohort of patients who received their ﬁrst
primary elective THA for OA between 2002-2009 utilizing health
administrative databases fromOntario, Canada. We excluded those who
had received a primary or revision arthroplasty of the hip or knee prior
to April 1, 2002, and those whose ﬁrst procedure was non-elective (e.g.
for cancer, fracture, or external cause of injury), or who had a history of
inﬂammatory arthritis. Among eligible THA recipients with OA, those
who had received1 intra-articular injection by a radiologist in the ﬁve
years prior to their THAwere identiﬁed. Those with 2+ injections in the
six months pre-THA or 3+ injections in the ﬁve years pre-THA were
excluded to avoid patients who received facet joint injections for lower
back pain. Logistic regression was used to determine the relationship
between occurrence of injection (none, 1-5 years, 6-12 months and
within 6 months of surgery) and revision within 2y of THA, after
controlling for potential confounders (income quintile, rurality, and
provider volume). A propensity score for receipt of an injection in the
6months prior to surgery was developed, and used to match these
patients to those who did not receive an injection in the 5years prior to
the THA. Rates of revision were compared between these groups to
determine the number needed to harm (NNH).
Results: Between April 1, 2002 and March 31, 2009, we identiﬁed
37,536 primary, elective THA recipients with OA. 5,907 had received an
intra-articular hip injection performed by a radiologist in the ﬁve years
preceding their surgery: 999 < 6months prior to surgery; 702 6months
to < 1y ; 783 1-5years). The mean time from intra-articular injection to
the index THA was 322d (median: 221d, IQR: 293d). Patients that had
an injection in the six months preceding surgery had increased odds for
revision within two years relative to patients who did not have an
injection (adjusted OR 2.24; 95% CI 1.44, 3.48; p¼0.0003). There was no
difference in the odds for revision for patients who received their
injection 6-12 months or 1-5years before surgery (6-12months:
adjusted OR 0.86; 95% CI 0.38, 1.94; p¼0.7156; 1-5years: adjusted OR
0.77; 95% CI 0.34, 1.74; p¼0.5135), relative to patients who did not
receive an injection pre-THA. Propensity score matching matched 986
patients with an intra-articular injection in the 6months prior to
surgery (99% of potential cases) with 2,958 patients who did not have
an injection in that time frame (8% of potential controls). After
matching, the rates of early revision in the injection and non-injection
groups were 2.23% (22/986) and 1.05% (31/2,958) (p¼0.005), respec-
tively. The number needed to harm, for THA recipients who had an
injection <6months prior to the surgery, was 84 patients.
Conclusions: Occurrence of an intra-articular injection in the 6months
prior to a primary elective THA for OA was associated with increased
risk for revision arthroplasty. Further research is needed to determine
whether this increased risk varies in relation to the solution used in the
intra-articular injection (corticosteroids versus hyaluronic acid prod-
ucts) and potential explanations for the relationship.4
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Purpose: There is an interest in using Magnetic Resonance Imaging
(MRI) to identify pre-radiographic changes in osteoarthritis (OA) and
identify features that indicate risk for disease progression. The purpose
of this study is to identify image features derived fromMRI T2maps that
can accurately predict OA progression prior to clinically signiﬁcant
symptomatic and radiographic presentation. In normal cartilage, there is
a spatial distribution of cartilage MRI T2 values that is strongly
